A personal account reported by UK media says the diabetes drug Mounjaro (tirzepatide) helped one woman lose weight and improve symptoms she attributes to PMOS, a hormone-related condition. The article describes Natalie Lavergne losing about five and a half stone while using Mounjaro and says the treatment also eased the symptoms she says have affected her life. The piece further states she plans to stop Mounjaro and switch to the “Wegovy Pill,” referring to an upcoming or newly available oral form of semaglutide marketed as Wegovy.
The reports are based on the woman’s experience and do not provide additional clinical data, comparative results, or details about her medical assessment. They also do not confirm long-term outcomes or whether symptoms will return after stopping the medication. Overall, the coverage presents Mounjaro as part of her weight-loss and symptom-management experience and frames her next step as a planned change to a different GLP-1–based therapy.
